
    
      The purpose of this study is to define the maximum tolerated dose (MTD) and the
      pharmacokinetic (PK) profile of the anti-FMS-like tyrosine kinase 3 (FLT3) monoclonal
      antibody IMC-EB10, administered weekly in participant with acute lymphoblastic leukemia (AML)
      who have failed to achieve complete remission to a standard induction regimen, relapsed after
      response to previous antileukemia therapy, or are not eligible for potentially curative or
      approved salvage options.
    
  